Nurix Therapeutics is trading at $16.07, up 5.69%, alongside a broad market rebound, with major indexes up more than 0.5%. - No fresh company-specific catalyst was identified for November 9. - Recent news includes a planned ASH presentation of updated bexobrutideg data, announced November 5; Sanofi’s decision to end the SAR448272 program remains a recent negative development, not a new catalyst today. - Intraday volume or activity details were unavailable in the reviewed sources.